Company news: Novo Nordisk

Share this article:
Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir. Victoza sales were up 253% to around $444 million while sales of modern insulins were up 10% and North American sales rose 15%.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions